Kim Dong-Joo, Choi Mun-Ki, Jeong Jin-Tak, Lim Jung-Taek, Lee Han-Byoel, Han Wonshik, Lee Sang-Kwon
J Biomed Nanotechnol. 2016 Apr;12(4):645-55. doi: 10.1166/jbn.2016.2200.
The separation of circulating tumor cells (CTCs) from the blood of cancer patients with high sensitivity is an essential technique for selecting chemotherapeutic agents at a patient-by-patient level. Recently, various research groups have reported a nanostructure-based platform for rare cell capture due to its high surface area and 3D nanotopographic features. However, evaluation of capture sensitivity based on chemical modification of the nanostructure surface has not yet been performed. Here, we evaluated the capture sensitivity for CTCs from the blood of three patients diagnosed with stage IV metastatic breast cancer by using the following three platforms: streptavidin-conjugated silicon nanowire (STR-SiNW), poly-l-lysine-coated silicon nanowire (PLL-SiNW), and poly-l-lysine-coated glass (PLL-glass). The number of evaluated CTCs on STR-SiNW, PLL-SiNW, and PLL-glass were 16.2 ± 5.5 cells, 7.3 ± 2.9 cells, and 4.7 ± 1.5 cells, respectively, per 0.5 ml. Therefore, we suggest that the STR-SiNW platform is highly adaptable for the quantitative evaluation of CTCs from the blood of cancer patients in the clinical setting.
从癌症患者血液中高灵敏度地分离循环肿瘤细胞（CTC）是在个体水平上选择化疗药物的一项关键技术。最近，由于其高表面积和三维纳米拓扑特征，各研究团队报道了一种基于纳米结构的稀有细胞捕获平台。然而，尚未对基于纳米结构表面化学修饰的捕获灵敏度进行评估。在此，我们使用以下三种平台评估了从三名被诊断为IV期转移性乳腺癌患者血液中捕获CTC的灵敏度：链霉亲和素偶联的硅纳米线（STR-SiNW）、聚-L-赖氨酸包被的硅纳米线（PLL-SiNW）和聚-L-赖氨酸包被的玻璃（PLL-玻璃）。每0.5毫升血液中，STR-SiNW、PLL-SiNW和PLL-玻璃上评估的CTC数量分别为16.2±5.5个细胞、7.3±2.9个细胞和4.7±1.5个细胞。因此，我们认为STR-SiNW平台非常适合在临床环境中对癌症患者血液中的CTC进行定量评估。
